Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:AURA NASDAQ:CLYM NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.50$4.44$1.34▼$5.15$628.49M0.761.25 million shs4.32 million shsAURAAura Biosciences$6.34$7.20$4.73▼$9.53$655.47M0.39486,903 shs1.26 million shsCLYMClimb Bio$11.45$10.41$1.17▼$12.48$655.66M0.091.19 million shs1.25 million shsSPROSpero Therapeutics$2.28$2.68$1.80▼$3.22$132.01M1.451.74 million shs7.16 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%+4.17%-0.66%+21.95%+216.90%AURAAura Biosciences0.00%-1.09%-15.13%-3.21%+3.93%CLYMClimb Bio0.00%+0.09%+8.84%+87.40%+830.89%SPROSpero Therapeutics0.00%-20.00%-13.31%-3.80%-22.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.50$4.44$1.34▼$5.15$628.49M0.761.25 million shs4.32 million shsAURAAura Biosciences$6.34$7.20$4.73▼$9.53$655.47M0.39486,903 shs1.26 million shsCLYMClimb Bio$11.45$10.41$1.17▼$12.48$655.66M0.091.19 million shs1.25 million shsSPROSpero Therapeutics$2.28$2.68$1.80▼$3.22$132.01M1.451.74 million shs7.16 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%+4.17%-0.66%+21.95%+216.90%AURAAura Biosciences0.00%-1.09%-15.13%-3.21%+3.93%CLYMClimb Bio0.00%+0.09%+8.84%+87.40%+830.89%SPROSpero Therapeutics0.00%-20.00%-13.31%-3.80%-22.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50155.56% UpsideAURAAura Biosciences 2.25Hold$20.50223.34% UpsideCLYMClimb Bio 3.07Buy$21.7389.76% UpsideSPROSpero Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest SPRO, AURA, CLYM, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/12/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$17.006/11/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $20.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.006/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/12/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026AURAAura Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.005/12/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.00(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$8.37M75.12N/AN/A$0.85 per share5.29AURAAura BiosciencesN/AN/AN/AN/A$2.16 per shareN/ACLYMClimb BioN/AN/AN/AN/A$3.36 per shareN/ASPROSpero Therapeutics$54.77M2.41$0.15 per share14.98$1.05 per share2.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)AURAAura Biosciences-$106.19M-$1.74N/AN/AN/AN/A-78.12%-64.08%8/12/2026 (Estimated)CLYMClimb Bio-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)SPROSpero Therapeutics$8.57M$0.249.50N/AN/A24.90%35.58%24.95%8/11/2026 (Estimated)Latest SPRO, AURA, CLYM, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/13/2026Q1 2026SPROSpero Therapeutics-$0.18-$0.13+$0.05-$0.13$0.26 million$0.26 million5/11/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million5/7/2026Q1 2026CLYMClimb Bio-$0.26-$0.20+$0.06-$0.20N/AN/A3/30/2026Q4 2025AURAAura Biosciences-$0.43-$0.37+$0.06-$0.37N/AN/A3/26/2026Q4 2025SPROSpero Therapeutics-$0.20$0.53+$0.73$0.53$26.00 million$41.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/ASPROSpero Therapeutics$0.062.63%N/A25.00%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03AURAAura BiosciencesN/A7.097.09CLYMClimb BioN/A27.8627.86SPROSpero TherapeuticsN/A10.5010.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%AURAAura Biosciences96.75%CLYMClimb Bio69.76%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%AURAAura Biosciences6.30%CLYMClimb Bio2.60%SPROSpero Therapeutics2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableAURAAura Biosciences50103.39 million96.87 millionNot OptionableCLYMClimb Bio957.26 million55.77 millionN/ASPROSpero Therapeutics15057.90 million56.22 millionOptionableSPRO, AURA, CLYM, and ACRS HeadlinesRecent News About These CompaniesBiggest stock movers Thursday: INTC, KR, ACN, and moreJune 18 at 1:30 PM | seekingalpha.comSpero shares jump after FDA clears first oral carbapenem antibiotic for US market (SPRO)June 18 at 1:30 PM | msn.comGSK's Utebzi Wins FDA Nod for Complicated Urinary Tract InfectionsJune 18 at 10:01 AM | zacks.comSpero Therapeutics, Inc.: Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)June 18 at 8:29 AM | finanznachrichten.deFDA approves first oral carbapenem therapy for cUTIsJune 17 at 8:01 PM | thepharmaletter.comTUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)June 17 at 12:36 PM | globenewswire.comSpero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold)June 10, 2026 | seekingalpha.comSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business UpdateMay 13, 2026 | globenewswire.comEsther Rajavelu Sells 25,240 Shares of Spero Therapeutics (NASDAQ:SPRO) StockMay 7, 2026 | insidertrades.comSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026May 5, 2026 | globenewswire.comSpero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business UpdateMarch 26, 2026 | globenewswire.comSpero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026March 18, 2026 | globenewswire.comSpero Therapeutics: Tebipenem's FDA Path Supports A Speculative BuyFebruary 11, 2026 | seekingalpha.comSpero Therapeutics (NASDAQ:SPRO) Insider Sells $207,484.12 in StockFebruary 10, 2026 | insidertrades.comInsider Selling: Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares of StockFebruary 6, 2026 | insidertrades.comWhy Spero Therapeutics, Inc.’s (SPRO) Stock Is Up 7.48%February 4, 2026 | aaii.comAFormer Spero execs fined by SEC over antibiotic efficacy claimsJanuary 20, 2026 | fiercebiotech.comFSpero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including PyelonephritisDecember 19, 2025 | globenewswire.comIs Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?December 15, 2025 | finance.yahoo.comSpero Therapeutics (SPRO) price target decreased by 20.00% to 4.08December 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026Slice of the Pie: Why Yum’s Deal Lifts QSRBy Jeffrey Neal Johnson | June 3, 2026Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround ProgressBy Jennifer Ryan Woods | June 11, 2026Short Sellers Are Piling Into Wingstop, But Analysts See Big UpsideBy Jennifer Ryan Woods | June 10, 2026Cooking Up Profits: Cracker Barrel’s TurnaroundBy Jeffrey Neal Johnson | June 14, 2026SPRO, AURA, CLYM, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.50 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$4.31 -0.19 (-4.20%) As of 06/18/2026 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Aura Biosciences NASDAQ:AURA$6.34 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$6.34 +0.00 (+0.08%) As of 06/18/2026 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Climb Bio NASDAQ:CLYM$11.45 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$11.53 +0.08 (+0.70%) As of 06/18/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Spero Therapeutics NASDAQ:SPRO$2.28 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$2.28 +0.00 (+0.18%) As of 06/18/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
